Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated June 6, 2019, discloses the results of the Annual Meeting of Stockholders held by Arcus Biosciences, Inc. on that date. The company is incorporated in Delaware and its common stock trades on the New York Stock Exchange under the symbol RCUS.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial statements or operational metrics.
Material Changes
No material financial changes or operational updates are reported in this filing. The document solely details the outcome of stockholder votes regarding board elections and auditor ratification.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a procedural report of the annual meeting outcomes.
Key Facts for Investors
- Director Elections: Stockholders elected Yasunori Kaneko, M.D., and Kristen Hege, M.D., to serve until the 2022 Annual Meeting.
- Voting Results (Proposal 1): Dr. Kaneko received 22,774,906 votes for; Dr. Hege received 23,846,590 votes for. Significant broker non-votes (4,387,607) were recorded for both nominees.
- Auditor Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- Voting Results (Proposal 2): The proposal received 28,215,398 votes for, 129,354 votes against, and 2,830,723 abstentions.